title: The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.
abstract: BACKGROUND
  This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI.
  
  
  METHODS
  The PET Core has used [(18)F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [(18)F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition.
  
  
  RESULTS
  Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale.
  
  
  CONCLUSIONS
  The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.
authors.affiliation: Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA. Electronic address: jagust@berkeley.edu.
authors.forename: William J
authors.initials: WJ
authors.lastname: Jagust
authors.affiliation: Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Landau
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Koeppe
authors.affiliation: Banner Alzheimer Institute, Phoenix, AZ, USA.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Reiman
authors.affiliation: Banner Alzheimer Institute, Phoenix, AZ, USA.
authors.forename: Kewei
authors.initials: K
authors.lastname: Chen
authors.affiliation: Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Chester A
authors.initials: CA
authors.lastname: Mathis
authors.affiliation: Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Julie C
authors.initials: JC
authors.lastname: Price
authors.affiliation: Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA.
authors.forename: Norman L
authors.initials: NL
authors.lastname: Foster
authors.affiliation: Department of Neurology, Center for Alzheimer's Care, Imaging and Research, University of Utah, Salt Lake City, UT, USA.
authors.forename: Angela Y
authors.initials: AY
authors.lastname: Wang
mesh_terms: D000544:Alzheimer Disease / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D053327:Apolipoprotein E4 / Q000235:genetics; D001921:Brain / Q000000981:diagnostic imaging*; D001931:Brain Mapping; D003072:Cognition Disorders / Q000209:etiology; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D021621:Imaging, Three-Dimensional; D008137:Longitudinal Studies; D049268:Positron-Emission Tomography
chemical_list: D053327:Apolipoprotein E4; D019788:Fluorodeoxyglucose F18
keywords: Alzheimer's disease; Amyloid; Fluorodeoxyglucose; Mild cognitive impairment; PET imaging